Polydatin as a natural ClpP modulator for combating methicillin-resistant Staphylococcus aureus infection

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Methicillin-resistant Staphylococcus aureus (MRSA) is a significant cause of hospital-acquired infections.
• Multidrug resistance and high virulence make MRSA a therapeutic challenge.
• Targeting bacterial virulence offers an alternative to traditional antibiotics.

Purpose of the Study:

• To investigate polydatin, a natural compound, as a potential antivirulence agent against MRSA.
• To explore polydatin's mechanism of action, specifically its inhibition of caseinolytic protease P (ClpP).

Main Methods:

• Enzymatic assays to assess ClpP inhibition.
• In vitro studies on bacterial growth, hemolytic activity, virulence gene expression, adhesion, and invasion.
• In vivo evaluation in a murine pneumonia model.

Main Results:

• Polydatin inhibited ClpP and reduced key virulence factors (Hla, PVL, RNAIII).
• Polydatin impaired bacterial adhesion and host cell invasion.
• Polydatin treatment alleviated MRSA-induced pneumonia in mice, reducing bacterial load and inflammation.

Conclusions:

• Polydatin attenuates MRSA pathogenicity by targeting ClpP-mediated virulence regulation.
• Polydatin is a promising antivirulence candidate for developing alternative MRSA therapies.